Drug and biologically active substance carrier for treating and diagnosing and method for preparing it

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutics, namely to a drug substance and a biologically active substance carrier for treating and diagnosing representing a nanoparticle having a ferric oxide coated zirconium dioxide nucleus having a nearly spherical shape and a size of 15-100 nm, and to a method for preparing the carrier wherein to a solution containing iron II, iron III and zirconium IV cations, having pH=7.5; an ammonium mixture is added to pH=8-9 at a rate providing preparing t nanoparticles of a pre-set size of 15-100 nm; the product is recovered by centrifugation, washed and lyophilised.

EFFECT: invention provides creating the new drug substance and the biologically active substance carrier.

4 cl, 2 ex, 1 tbl, 3 dwg

 

The group of inventions relates to medicine, the pharmaceutical industry and biotechnology, namely the carrier for drugs and biologically active substances for the treatment and diagnosis and the method of its production. The media can be used to deliver drugs or other biologically active substances in the human or animal and controlled release in the diagnosis and treatment. The method of receiving media may be used in its production.

Known for the preparation of liquid compositions containing nanostructured metal-containing particles with high bactericidal, catalyst, corrosion and magnetic activity, and the method of its production (EN 2322327, publ. 20.04.2008). Nanostructured metallic and bimetallic particles and nanostructured particles of oxides and sulfides obtained by recovery of metal ions solvated electrons and radicals in the system of reverse micelles in the absence of oxygen. The way to obtain the micellar solution is stable metal-containing nanostructured particles includes preparation of back-micellar dispersion-based solution of surfactants in nonpolar solvent, the introduction of water or water-alcohol solution of ions of metal salts, holding in front of nachampassak recovery stirring or ultrasonic treatment variance, guariroba and restoration of solvated electrons and radicals generated during the impact on the variance of ionizing radiation. The invention provides controlled getting in the liquid phase stable nanosized metallic, bimetallic particles and nanostructures of oxides and sulfides of metals.

The disadvantages of the above liquid-phase compositions and the method of their derivation should include the complexity of the synthesis process, which consists in the need to ensure an inert atmosphere containing no oxygen (guariroba), preliminary preparation of back-micellar dispersion-based solution of surfactants in nonpolar solvent, the application of an ionizing radiation source to generate solvated electrons and radicals.

A well-known carrier, representing the nanoparticles consisting of superparamagnetic particles of iron oxide or of pure iron having an oxide layer, and associated with at least one therapeutically active substance through a linker (EN 2007141588/15, Appl. 12.04.06; publ. 20.05.09). Magnetic nanoparticles (MN) of iron oxides have low toxicity and stability of the physical characteristics that led to their application in Biomedicine. A famous bearer is the closest to the technical eskay nature of the claimed carrier for drugs and biologically active substances for the treatment and diagnosis.

However MNCH of magnetite have a complex, angular shapes other than spherical, and broad polydisperse size distribution. To use them you need to apply special processing modes, surface-active substances (surfactants) and methods for their introduction into the solution. For medical and preparative control delivery of biologically active substances on the carrier, in addition to the target component, it is necessary to put a marker (fluorescein or similar connection).

There is a method of producing nanoparticles of a metal oxide, comprising the processing of the original inorganic salts of the corresponding metal in the environment of the reaction gas at high temperatures, in which the powder source of salt is treated in a current of steam at a feed rate of 20-30 ml/min and a temperature of 500-900°C (EN 2384522, publ. 20.03.2010). The method is based on the reaction of thermal hydrolysis, in which a chemical reaction occurs with the formation of the oxide of the corresponding metal and gaseous oxide. The method allows to obtain a powder product nanoparticles of metal oxides with a particle size of 3-10 nm. This method adopted by the authors as the closest analogue of the claimed method.

The disadvantages of the method include its complexity, the need to use special equipment and high temperatures. In addition, nanoc Stacy metal oxide with a size of 3-10 nm cannot be used as a carrier for drugs, as quickly excreted. For these purposes, the required particle size of 15-100 nm.

The technical result achieved by the group of inventions is to create a carrier for drugs and biologically active substances for the treatment and diagnosis form nanoparticles is close to spherical, and set size, from about 15 to 100 nm.

The claimed technical result is achieved in a carrier for drugs and biologically active substances for the treatment and diagnosis, representing the nanoparticles containing iron oxide, in which the nanoparticle has a core of Zirconia-coated iron oxide, a shape close to spherical, and the size in the range 15-100 nm.

Preferably, the nanoparticles have a size of 15-20 nm with kernel Zirconia size of 5-10 nm.

The claimed technical result is also achieved in a method of producing a carrier for drugs and biologically active substances for the treatment and diagnosis, including the processing of the original inorganic salts, in which the solution containing cations of iron II and iron III and zirconium IV, pH=7,5 add ammonia mixture to pH=8-9 with speed, providing nanoparticles of a given size in the range 15-100 nm, the product is separated by centrifugation, washed is subjected to freeze drying.

For nanoparticles with a size of 15-20 nm with kernel Zirconia size of 5-10 nm cations of iron II, iron III, and zirconium IV in solution taken in a molar ratio of 2:1:1 and add aqueous ammonia mixture containing 25% ammonium hydroxide and 1% of ammonium acetate, at a speed of 4 ml/min

Through the use of zirconium dioxide kernel shape close to spherical nanoparticles. The media can be used without additional processing for sorption of active substances. The form of nanoparticles, which is close to spherical, provides uniform coverage of its drug using it as a media, as well as the greatest stability of the obtained colloidal solution by settling and stratification.

The presence of zirconium in the core may be a marker for quantification of nanoparticles in tissues for laboratory studies on the toxicity, biocompatibility and biodistribution. It is enough to control content in tissues Zr number of physical and chemical methods of analysis, such as atomic emission spectroscopy of tissues.

Since the solubility product of zirconium hydroxide (CR=2·10-24below the solubility product of iron oxide II (PR=5·10-10) and hydroxide of iron III (PR=3,2·10-17), adding ammonia mixture is definitely the slow speed in the first stage are formed nanoparticles of zirconium hydroxide, having a shape close to spherical. Then at the core of zirconium hydroxide begins to feel magnetite - a mixture of oxides of iron II and iron III.

In aqueous solutions of ions of zirconium and iron hydrolyzed, followed by the interaction with HE-groups leads to the formation of hydroxides.

The transition from the hydroxides to oxides of metals occurs at the stage of freeze drying.

The claimed method provides the kernel form and the final form of nanoparticles, which is close to spherical, and the size of the nanoparticles is from about 15 to 100 nm without the use of sophisticated technology and high temperatures. Nanoparticles smaller than 10 nm are quickly washed out of the body by filtration through the kidney filter. Nanoparticles larger than 100 nm is rapidly eliminated from the bloodstream by the elements of the reticulo-endothelial system.

The appointment of a mixture of ammonium due to the following.

The ammonia solution, on the one hand, is a source of Oh-groups necessary for the formation of hydroxides. On the other hand, the ammonia binds iron ions, preventing premature precipitation of the hydroxides of iron. On this basis, in addition to the ammonia solution, other alkali is not suitable for obtaining this kind of nanoparticles, as iron hydroxide and zirconium will drop randomly.

When adding a mixture of ammonium hydroxide is formed qi is Konya, the particles which ammonium acetate adsorbed, as it is in the form of CH3Soo-therefore, the surface of the particle acquires a negative charge and attracts ions of iron II and iron III from the solution according to the laws of electrostatics with subsequent formation of a shell of iron hydroxide on the surface of the hydroxide of zirconium, and not randomly in solution. Ammonium acetate is a good surfactant, and it does not require a large number.

By varying the ratio of cations, the feed rate of the ammonia mixture and the final pH value, it is possible to vary the size of the Zirconia core and the final size of the nanoparticles in the range of about 15-100 nm.

As water-soluble salts containing the cations of iron (II), iron (III) and zirconium (IV), can be used sulfates, nitrates, chlorides, bromides.

For nanoparticles with a size of 15-20 nm with kernel Zirconia size of 5-10 nm ammonium mixture contains 25% ammonium hydroxide and 1% ammonium acetate. The molar ratio of cations of iron II, iron III, and zirconium IV chosen experimentally and is 2:1:1. The feed rate of ammonia mixtures are also selected experimentally and is 4 ml/min for Both of these parameters, namely the ratio of reactants and the rate of feed of the ammonia mixture, provide education in the solution of the NAS is of Zirconia particles with a size of 5-10 nm. Then these particles starts to feel magnetite, up to a specified pH=8-9, which provides the final particle size of 15-20 nm.

In Fig. 1 presents the results of x-ray diffraction analysis of nanoparticles with core ZrO2and shell Fe3O4Fig. 2 is a micrograph of the nanoparticles:andthe nanoparticles of Fe3O4b - nanoparticles with core ZrO2and shell Fe3O4Fig. 3 - zirconium content in the tissue samples.

The method is carried out, for example, as follows.

In a solution containing salts of cations of iron II, iron III, and zirconium IV, with constant stirring and standard temperature (25 deg. (C) at a given speed, add ammonia mixture consisting of ammonium hydroxide solution and a solution of ammonium acetate. The synthesis is carried out before fixing a rich black color and establishing pH = 8-9. The obtained colloidal product is separated by centrifugation and washed 4 times with distilled water. For the preparation of dry samples obtained nanoparticles were filtered and subjected to freeze drying at a temperature of -48 degrees C for 48 hours.

The group of inventions is illustrated by the following examples.

1. To a solution containing a mixture of sulphate of iron II, iron III, and zirconium nitrate in a molar ratio of 2:1:1 and a volume of 700 ml, with a constant is remesiana was added a mixture of 25% ammonium hydroxide solution and 1% solution of ammonium acetate at a speed of 4 ml/min. Thus, the ratio of iron and ammonium acetate was 2:1:0.1. The synthesis was carried out before fixing a rich black color and establishing pH=8-9. The next day received a colloidal product was separated by centrifugation and washed 4 times with distilled water. For the preparation of a dry sample of the obtained nanoparticles was filtered and subjected to freeze drying at a temperature of -48°C for 48 hours.

To confirm the chemical composition of the obtained nanoparticles was performed x-ray diffraction analysis. The results of x-ray diffraction analysis (figure 1) confirm the chemical composition of the nanoparticles.

Specific surface area of the nanoparticles was determined by a simplified method BET on installing Klyachko-Gurvich. Specific surface area was about 100 m2/g, which indicates a good adsorption capacity of the nanoparticles.

To determine the size of nanoparticles used a method of raster scanning electron microscopy.

For comparison were obtained nanoparticles of pure magnetite. Micrograph of nanoparticles of pure magnetite and claimed the media is presented in figure 2.

Nanoparticles of pure magnetite (figure 2.and) have a complex, angular shapes and a wide polydisperse size distribution. Nanoparticles declared media, in contrast, have a shape close to spherical, and the minimum level of 15-20 nm when the kernel size of 5-10 nm (figb). This nanomaterial can be used without additional processing for sorption of active substances.

For the implementation of targeted delivery of nanoparticles in the tissue of the experimental animals was used solenoid with parameters listed in table 1.

Table 1
№p/pValue
1The diameter of the solenoid (D)mm35.0
2The length of the working part of the solenoid (l)mm40.0
3The number of turns (N)800
4Wire diameter (d)mm0,22
5Resistance (R)Ohm40
6The supply voltage (U)20.0
7The current strength (I), And0.5

The most effective distance from the center of the solenoid to the object of delivery has identified the mA is tematicheskie, and it was 7 mm.

The experiments were performed on rats male Wistar, weighing 250-300 grams. Animals were divided into following groups:

1. Control, within 10 minutes produced intravenous 0.9% NaCl in a volume of 1 ml, n = 5.

2. Intravenous administration of nanoparticles at a dose of 1 mg/ml without exposure to electromagnetic fields, n = 5.

3. The introduction of nanoparticles in the dosage of 1 mg/ml of exposure to electromagnetic fields in hip rats for 10 minutes, n = 5.

20 minutes after the start of injection of physiological solution or suspension of the nanoparticles was carried out by removing the animal from the experiment and took the hip muscles for analysis. Collected tissue samples were dried in a dry-heat Cabinet at a temperature of 90°C for 24 hours, then crushed to a powder and dissolved in sulfuric acid. Analysis of the resulting sulfuric acid solution of the zirconium content was performed atomic-emission method with inductively coupled plasma (AESOP) by a standard method.

Analysis of the results (figure 3) showed that in the control zirconium is not detected. In the experiment with the introduction of the nanoparticles and the influence of the electromagnetic field is observed the maximum level of zirconium, which indicates the accumulation of the nanoparticles and the possibility of targeted drug delivery in tissue lower konecne the property.

2. The nanoparticle synthesis was carried out as in example 1, when the molar ratio of cations of iron II, iron III, and zirconium IV 3:1:2. The feed rate of ammonia mixture was 10 ml/min the resulting nanoparticles had a size of 40-50 nm and the kernel size 18-20 nm.

Use of the claimed group of inventions provides a carrier for drugs and biologically active substances for the treatment and diagnosis form nanoparticles is close to spherical, and a specified amount of from about 15 to 100 nm.

1. A carrier for drugs and biologically active substances for the treatment and diagnosis, representing the nanoparticles containing iron oxide, wherein the nanoparticle has a core of Zirconia-coated iron oxide, a shape close to spherical, and the size in the range 15-100 nm.

2. The carrier according to claim 1, wherein the nanoparticle has a size of 15-20 nm with kernel Zirconia size of 5-10 nm.

3. A method of obtaining a carrier for drugs and biologically active substances for the treatment and diagnosis, including the processing of the original inorganic salts, characterized in that the solution containing cations of iron II, iron III, and zirconium IV, pH=7,5 add ammonia mixture to pH=8-9 with speed, providing nanoparticles of a given size in p is adalah 15-100 nm, the product is separated by centrifugation, washed and subjected to freeze drying.

4. The method according to claim 3, characterized in that the cations of iron II, iron III, and zirconium IV take in a molar ratio of 2:1:1 and add aqueous ammonia mixture containing 25% ammonium hydroxide and 1% of ammonium acetate, at a speed of 4 ml/min



 

Same patents:

FIELD: nanotechnology.

SUBSTANCE: inventions can be used in the field of nanotechnologies and inorganic chemistry. The method of production of boride nanofilm or nanowire comprises depositing on the alumina nanowire or on fiberglass of low-melting glass in vacuum the multiple alternating layers of titanium and boron, after which the resulting composition is gradually heated to a temperature of 1500°C. In another embodiment, the method of production of boride nanofilm comprises depositing of titanium boride layer of nanothickness on alumina nanofilm of the gas phase comprising titanium halogenide and boron.

EFFECT: inventions enable to obtain boride nanostructures.

4 cl, 2 ex

FIELD: chemistry.

SUBSTANCE: coating is based on titanium carbonitride with addition of additional elements which provide the required set of mechanical and tribological properties, as well as biologically active and antibacterial properties. Overall concentrations of basic and additional elements are in the following ratio: 1,2<XiYj<20, where Xi is the overall concentration of basic elements Ti, C, N in the coating, Yj is the overall concentration of additional elements Ag, Ca, Zr, Si, O, P, K, Mn in the coating.

EFFECT: coating has high hardness, low modulus of elasticity, high value of elastic recovery, low coefficient of friction and rate of wear in different physiological media.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to the application of a solid medicinal product, which is heated under the impact of an alternating magnetic field, for further therapeutic treatment after surgical ablation of tumours and cancerous ulcers. The medicinal product represents a surgical implant, presented in the form of a physiologically acceptable fabric, sponge or film. The medicinal product contains magnetic particles, which generate heat when excited by an impact of the alternating magnetic field, and in this way, heat the medicinal product.

EFFECT: invention ensures considerable improvement of further treatment after operation on cancerous tumour in comparison with chemotherapy.

21 cl, 14 ex

FIELD: chemistry.

SUBSTANCE: memristor devices are nonvolatile memory devices and can be used to design computer systems based on an artificial neural network architecture. The present device consists of an active layer situated between two current-conducting layers with which it is in electrical contact. The active layer has a resistive switching property and is a double-layer oxide structure HfAlxOy/HfO2. The HfAlxOy layer has high solubility and high equilibrium concentration of oxygen vacancies, and HfO2 is a layer with low solubility of vacancies. The current-conducting layers are made of titanium nitride or tungsten nitride. A super-thin layer of ruthenium oxide with thickness of not less than 0.5 nm is deposited on the HfO2/TiN boundary surface.

EFFECT: high stability of modes of switching resistance to a low- and high-ohmic state, low switching voltage, high technological compatibility with existing silicon-based microcircuit manufacturing processes.

3 cl, 2 dwg

FIELD: biotechnology.

SUBSTANCE: as the present invention the method for production of polyfunctional magnetic nanoparticles based on bacterial magnetosomes and the hybrid protein MGG is provided, which enables to obtain magnetosomes binding immunoglobulins of the IgG class on the fragment Fc. The result is achieved in that in the lipid membrane of bacterial magnetosomes by ultrasonic treatment the hybrid protein MGG is integrated, which amino acid sequence comprises the transmembrane domain and the binding area of immunoglobulins.

EFFECT: obtaining polyfunctional magnetic sorbent bearing on the surface of magnetic nanoparticles of ligand, that enable to connect to the particles the immunoglobulins of IgG class.

4 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a method of obtaining mineral silicic water (MSW), intended for application for medical purposes. The method of obtaining includes hydrolysis of tetraethoxysilane in the TEOS mixture: ethanol: water, acidified by HCl. Nanosol is obtained at a temperature of 55-65°C for 1.5 hours with evaporation of ethanol to the volume reduction by 1/3, then, dilution of the obtained nanosol with a physiological solution NaCl is carried out in 2 steps with equal portions of the physiological solution, preliminarily heated to 40-50 in a ratio of volumes of the initial nanosol: physiological solution 1:7 with 15-minute interval. After each dilution a temperature of the solution is kept in the range of 55-65°C.

EFFECT: increase of the compound application efficiency.

1 ex

FIELD: medicine.

SUBSTANCE: what is described is a method for preparing a nanostructured calcium-phosphate coating for medical implants consisting in sputtering a target of stoichiometric hydroxyapatite Ca10(PO4)6(OH)2 in high-frequency magnetron discharge plasma in the argon environment under pressure of 0.1-1 Pa and target power density of 0.1-1 W/cm2 for 15-180 min at a distance from the target to a carrier within the range of 40 to 50 cm, wherein the nanostructure is formed after a coating procedure in the process of the controlled thermal annealing at a temperature of 700-750°C for 15-30 min.

EFFECT: higher post-coating effectiveness of the production process.

4 dwg

FIELD: biotechnology.

SUBSTANCE: invention relates to compositions and polymeric materials for biomedical use, comprising silver nanoparticles (0.0005-0.02 wt %) stabilised by amphiphilic copolymers of maleic acid (0.0008-0.05 wt %), low molecular weight organic amines (0.0002-0.04 wt %) and water. In addition, the said composition may additionally comprise the polymeric structure-forming agent.

EFFECT: introduction to the composition of the polymer structure-forming agent enables to obtain the macroporous structured hydrogel materials having prolonged bactericidal and antifungal action.

3 cl, 2 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition for the delivery of a pharmaceutical agent to a focus of a disease. The composition contains a water-insoluble pharmaceutical agent which is paclitaxel, a pharmaceutically acceptable carrier which is albumin, preferentially human serum albumin. The relation (wt/wt) of albumin to paclitaxel makes 9:1. The pharmaceutical composition contains nanoparticles containing paclitaxel and albumin wherein the nanoparticles have a size of less than 200 nm.

EFFECT: administering the pharmaceutical composition according to the invention provides enhanced characteristics of the delivery of paclitaxel to the site of the disease and reduced adverse side effects.

24 cl, 5 tbl, 51 ex

FIELD: medicine.

SUBSTANCE: what is described is an umbrella device (occluder) with a modified coating layer for the left atrial appendage occlusion. The umbrella device (occluder) with the modified coating layer is made from a titanium nickelide alloy. It has the coating modified layer having a thickness of 80-95 nm which consists of at least two sub-layers: an external sub-layer having a thickness of 20-25 nm contains oxygen, carbon, silicone and titanium in the following ratio, at %: oxygen 25-65, carbon 1-5, silicone 1-10, titanium - the rest; an intermediate sub-layer having a thickness of 60-70 nm contains oxygen, carbon, silicone, titanium and nickel in the following ratio, at %: oxygen 5-30, carbon 1-5, silicone 10-30, nickel 1-50, titanium - the rest, with silicone reaching its maximum concentration at a depth of 30-35 nm from the surface. The modified coating layer of the umbrella device (occluder) has no evident interface of the sub-layers specific for a deposited layer.

EFFECT: umbrella device with the modified coating layer possesses biocompatibility, corrosive resistance and no toxicity.

9 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and is applicable for treating endogenous intoxication caused by high plasma bilirubin concentrations accompanying various pathologies. Substance of a method: a surface of a magnetically controlled sorbent agent is coated with hydrophobic ligands either in the form of 3-mercaptopropionic acid methyl ester, or in the form of polymeric octadecylhydrosilicic acid, or in the form of polymeric hydrosilicic acid, containing covalently attached octadecyl ligands. Magnetite micro- and nanoparticles are presented by Fe3O4. The total bilirubin recovery rate in the sorbent agent is determined by a lyophilised bovine serum dry powder. The bilirubin content is determined by formula: AB(%)=100-(A460 nm test/A460 nm reference)×100, wherein AB(%) is a percentage of the absorbed bilirubin; A460 nm test is an optical density of the solution contacted the sorbent agent; A460 nm reference is an optical density of the solution before contact with the sorbent agent; 460 nm is a wave length whereat bilirubin has the maximum optical absorption.

EFFECT: declared magnetically controlled sorbent agent possesses a developed specific surface, a reasonably good sorption capacity, as well as is characterised by a high degree of efficacy of bilirubin elimination from biological fluids, eg blood plasma (more than 30% lower bilirubin for one sorption cycle).

7 cl, 3 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a local antimicrobial composition having pH equal to min. 8, or buffered to pH equal to min. 7, containing 3-hydroxypyridine-2-carbonyloxy-bis(3-chloro-4-methylphenyl)borane in a combination with a carrier acceptable for local application.

EFFECT: invention provides creating an applicable formulation stable in an aqueous medium.

24 cl, 9 ex, 8 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to a pharmaceutical composition possessing antithrombotic, thrombolytic, immunomodulatory, anti-inflammatory action, normalising lipid and carbohydrate metabolism, more specifically to the pharmaceutical composition of the substance Pijavitum (hereinafter referred to Pijavitum) made from lyophilised medicinal leech. The above pharmaceutical composition is presented in the form of an enteric coated tablet.

EFFECT: coating prevents the active ingredients of Pijavitum from destruction under action of the enzymes and acid medium of the stomach.

FIELD: medicine.

SUBSTANCE: topical gel composition for treating erythema or a related symptom contains brimonidine 0.4 wt % to 0.6 wt %, preferentially in the form of brimonidine tartrate, a gelatinising agent, and at least one polyol. The topical application of the gel composition on the skin involved in erythema or having a manifestation of the related symptom has an effect on a serum or plasma profile of brimonidine with an average Cmax approximately 54±28 pcg/ml or less and an average AUC0-24h approximately 568±277 pcg·h/ml or less.

EFFECT: safe and effective treatment of erythema causing no inadequate drug-related side effects.

19 cl, 3 dwg, 5 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a formulation of a traditional Chinese medicine for treating bronchial asthma, and a method for preparing it. The traditional Chinese medical composition is prepared of pure herbal raw materials, including ephedra herb (Herba Ephedrae), ginkgo seeds (Semen Ginkgo), mulberry bark (Cortex Mori), skullcap root (Radix Scutellariae), bitter apricot seeds (Semen Armeniacae Amarum), pinellia rhinzomes (Rhizoma Pinelliae), perilla fruit (Fructus Perillae), foalfoot blossom (Flos Farfarae), red peony root (Radix Paeoniae Rubra), houttuynia herb (Herba Houttuyniae), trichosanthis root (Radix Trichosanthis), forsythia fruit (Fructus Forsythiae).

EFFECT: traditional Chinese medical composition is effective in treating bronchial asthma.

11 cl, 7 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: inhalation formulation in the form of aerosol for treating bronchial asthma and chronic obstructive pulmonary disease containing ipratropium bromide monohydrate as an active ingredient, ethanol absolute as a solvent, an aerosol particle size regulator as an adjuvant consisting of triethyl citrate and an acid specified in a group: citric acid, hydrochloric acid, orthophosphoric acid, 1,1,1,4-tetrafluoroethane (HFA-134a) and/or 1,1,1,2,3,3,3-heptafluoropropane (HFA-227ea) as a propellant in certain proportions.

EFFECT: increasing the respirable fraction and obtaining an optimised particle size distribution profile.

7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to biomedical compositions and methods of treating skin-affecting diseases, disorders and states.

EFFECT: compositions and methods of treating skin states, resulting from production of active forms of oxygen in a subject's skin, include application of local composition, containing an antioxidant compound with a lipophilic, mitochondria targeted cation, and which delivers therapeutically efficient quality of the antioxidant compound to fibroblasts and keratocytes of the skin.

13 cl, 2 tbl, 3 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention describes using S-amlodipine nicotinate in treating cerebrovascular disorders specified in a group: haemorrhagic stroke, ischemic stroke, including transient global ischemia. A pharmaceutical composition for treating the cerebrovascular disorders contains S-amlodipine nicotinate as an active ingredient in an effective amount of 0.1 mg to 50 mg per a dose, and pharmaceutically acceptable excipients. The composition represents either a tablet, or a solution for injections.

EFFECT: expanding the usage of S-amlodipine nicotinate.

2 cl, 3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: liposomal pharmaceutical composition includes a medicinal substance, lipids in form of phosphatidylcholine and cholesterol, and additionally contains minor positively charged component in form of cetylpyridinium chloride or stearyl ethanolamine.

EFFECT: high bioavailability of the medicinal substance through active transport to body organs and tissue.

10 cl, 3 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and pharmacology. The invention describes using ipidacrine for treating the locomotor diseases related to the solution of continuity. The above locomotor diseases are fractures, including delayed bone consolidation, delayed knitting, delayed fracture union, pathologic fracture, non-union fracture, and pseudoarthrosis. A pharmaceutical composition for treating the locomotor diseases contains ipidacrine as an active ingredient in an effective amount of 3 to 300 mg per a dose, and a pharmaceutically acceptable excipients. The composition is presented in the form of a tablet or a capsule.

EFFECT: invention extends the application of ipidacrine.

3 cl, 1 dwg, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: composition is used for producing vaccines for preventing infectious diseases to occur, treating allergy and malignant neoplasm cases. Various invention embodiments comprise virus, virus-like particle, viral capsid particle, fag or their recombinant forms covered with any desired antigen highly ordered and having repetitions that is achieved owing to specific interactions taking place. Multi-functional process based on cassette-type system (alpha-vaccine techniques) allows one to produce antigen-coated viral particles like hepatitis B virus or measles virus.

EFFECT: causing marked immune response.

44 cl, 7 dwg

Up!